Trial Profile
A Phase I Study of Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Omburtamab-I-124 (Primary) ; Liothyronine; Potassium iodide
- Indications Brain cancer; Glioma
- Focus Adverse reactions; First in man
- Sponsors Y-mAbs Therapeutics
- 25 May 2022 Status changed from discontinued to completed.
- 07 Feb 2022 Status changed from recruiting to discontinued as stopping rule was met per protocol as a result of the last two subjects experiencing dose limiting toxicities
- 08 Jun 2021 Results (n=46) assessing the safety of administering escalating doses and volumes of 124I-omburtamab by convection-enhanced delivery in children with diffuse intrinsic pontine glioma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.